France has begun reimbursing the costs of obesity medications Mounjaro and Wegovy through its national healthcare system. This coverage extends to individuals diagnosed with obesity or diabetes, significantly increasing access to these treatments. Previously, these drugs were only available to a limited number of patients willing to pay out-of-pocket. The decision reflects a growing recognition of obesity as a serious health concern requiring medical intervention. Experts anticipate increased demand for the medications following the reimbursement announcement. This move aligns France with other countries exploring wider access to novel obesity treatments. The coverage aims to improve public health outcomes by addressing a prevalent and costly condition.